GeneDx Holdings Corp. Class A Common Stock (WGS) — 分析摘要
GeneDx Holdings Corp. Class A Common Stock(WGS)的市值为1.85十亿美元,最近一年的营收同比增长了+40.0%。净利润率为-4.9%。当前市盈率为-23.8倍。
核心要点
- 营收同比变化+40.0%
- 净利润率-4.9%
- 市盈率-23.8倍
与SERVICES-HEALTH SERVICES板块的其他公司相比,WGS的营收增长为+40.0%,市盈率为-23.8倍。
GeneDx Holdings Corp. Class A Common Stock (WGS)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -14.9% — 经营亏损显著
净利润较上一期下降 270.1%。
自由现金流由上一期为正转为负。
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
行业
SERVICES-HEALTH SERVICES
员工人数
1,300
总部
STAMFORD, CT
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。